WAKE FOREST UNIVERSITY HEALTH SCIENCES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix

Phase 2

Completed

Conditions: Carcinoma of the Appendix
Primary Peritoneal Cavity Cancer

Interventions: Drug: mitomycin C
Drug: oxaliplatin
Procedure: therapeutic conventional surgery
Other: quality-of-life assessment
Drug: hyperthermic intraperitoneal chemotherapy

First Posted Date: 2012-04-19

Last Posted Date: 2018-07-03

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 136

Registration Number: NCT01580410

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Phase 1

Completed

Conditions: Adenocarcinoma of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Adenocarcinoma of the Stomach
Squamous Cell Carcinoma of the Esophagus
Stage II Esophageal Cancer
Stage II Gastric Cancer
Stage III Esophageal Cancer
Stage III Gastric Cancer

Interventions: Drug: erlotinib hydrochloride
Drug: oxaliplatin
Drug: fluorouracil
Radiation: radiation therapy
Procedure: conventional surgery
Other: immunohistochemistry staining method
Procedure: positron emission tomography
Procedure: computed tomography
Procedure: laboratory biomarker analysis
Genetic: gene expression analysis
Radiation: fludeoxyglucose F 18

First Posted Date: 2012-03-22

Last Posted Date: 2018-07-02

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 9

Registration Number: NCT01561014

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Lung
Adenosquamous Cell Lung Cancer
Bronchoalveolar Cell Lung Cancer
Large Cell Lung Cancer
Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Squamous Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: cisplatin
Biological: pegfilgrastim
Drug: erlotinib hydrochloride
Other: laboratory biomarker analysis
Genetic: polymorphism analysis
Other: pharmacogenomic studies
Genetic: genetic linkage analysis
Drug: docetaxel

First Posted Date: 2012-03-20

Last Posted Date: 2018-06-29

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 45

Registration Number: NCT01557959

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Clear Cell Sarcoma of the Kidney
Metastatic Osteosarcoma
Ovarian Sarcoma
Recurrent Adult Soft Tissue Sarcoma
Recurrent Uterine Sarcoma
Stage III Adult Soft Tissue Sarcoma
Chondrosarcoma
Bone Cancer
Recurrent Osteosarcoma
Stage III Uterine Sarcoma

Interventions: Drug: therapeutic angiotensin-(1-7)
Other: laboratory biomarker analysis

First Posted Date: 2012-03-14

Last Posted Date: 2018-07-05

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 20

Registration Number: NCT01553539

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Healing Touch or Guided Imagery In Treating Pain, Fatigue, Nausea, and Anxiety in Patients Undergoing Chemotherapy

Not Applicable

Completed

Conditions: Anxiety Disorder
Fatigue
Pain
Malignant Neoplasm
Nausea and Vomiting

Interventions: Other: questionnaire administration
Procedure: therapeutic touch
Behavioral: management of therapy complications
Procedure: standard follow-up care

First Posted Date: 2012-03-14

Last Posted Date: 2018-07-05

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 244

Registration Number: NCT01553578

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia

Phase 2

Withdrawn

Conditions: Adult Acute Myeloid Leukemia With Del(5q)
Recurrent Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Promyelocytic Leukemia (M3)

Interventions: Drug: gemtuzumab ozogamicin
Other: laboratory biomarker analysis

First Posted Date: 2012-03-08

Last Posted Date: 2018-07-02

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT01548911

Cooperative Lifestyle Programs (CLIP-II)

Not Applicable

Completed

Conditions: Physical Disability
Obesity
Cardiovascular Disease

Interventions: Behavioral: Caloric restriction
Behavioral: Aerobic Training
Behavioral: Resistance Training

First Posted Date: 2012-03-07

Last Posted Date: 2018-08-15

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 249

Registration Number: NCT01547182

Locations: 🇺🇸
Kernersville YMCA., Kernersville, North Carolina, United States
🇺🇸
William G. White YMCA, Winston-Salem, North Carolina, United States
🇺🇸
Fulton YMCA, Winston-Salem, North Carolina, United States

Remote Ischemic Preconditioning Mechanism Study

Early Phase 1

Completed

Conditions: Pain

Interventions: Device: Remote Ischemic Preconditioning, Capsaicin, UV-B

First Posted Date: 2012-03-01

Last Posted Date: 2018-08-10

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 20

Registration Number: NCT01541436

Locations: 🇺🇸
WakeForestUBMC, Winston-Salem, North Carolina, United States

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

Phase 2

Completed

Conditions: Extrahepatic Bile Duct Cancer
Nausea
Vomiting
Stage II Pancreatic Cancer
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions: Drug: aprepitant
Drug: gemcitabine hydrochloride
Drug: capecitabine
Drug: fluorouracil
Procedure: radiation therapy
Other: questionnaire administration
Procedure: quality-of-life assessment
Procedure: nausea and vomiting therapy
Procedure: management of therapy complications

First Posted Date: 2012-02-17

Last Posted Date: 2018-08-15

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 22

Registration Number: NCT01534637

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking

Phase 2

Completed

Conditions: Lung Cancer
Prostate Cancer
Breast Cancer
Colorectal Cancer
Tobacco Use Disorder

Interventions: Drug: placebo
Drug: memantine hydrochloride

First Posted Date: 2012-02-17

Last Posted Date: 2021-09-28

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 130

Registration Number: NCT01535040

Locations: 🇺🇸
Wake Forest Cancer Center CCOP Research Base, Winston-Salem, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy